Anastrozole Powder
NDC Package 69988-0013-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Anastrozole powders is anastrozole is used to treat breast cancer in women after menopause. This formulation utilizes a powder delivery system. Marketed by Catalent Micron Technologies, Inc., this product is identified by NDC 69988-0013.

Identification & Billing

NDC Package Code
69988-0013-1
Package Description
1 BAG in 1 DRUM / 4.5 POWDER in 1 BAG
Product Code
69988-0013
11-Digit Billing Format
69988001301

Clinical Specifications

Proprietary Name
Anastrozole
Non-Proprietary Name
Anastrozole
Substance Name
Anastrozole
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
ANASTROZOLE 1 kg/1
Usage Information
Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Regulatory & Marketing

Labeler Name
Catalent Micron Technologies, Inc.
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
10-03-2005
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69988-0013-1 identifies a specific commercial package of 1 bag in 1 drum / 4.5 powder in 1 bag of Anastrozole (UNFINISHED drug), drug for further processing labeled by Catalent Micron Technologies, Inc.. This powder is formulated for use and contains anastrozole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Catalent Micron Technologies, Inc. on October 03, 2005. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

How is this Catalent Micron Technologies, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69988001301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
69988-0013-1
11-Digit CMS (5-4-2)
69988-0013-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.